VivoSim Labs (FRA:4OR) Tax Provision: €-0.00 Mil (TTM As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
38 GF Score
Price €3.49
GF Value €8.71
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Tax Provision?

VivoSim Labs FRA:4OR 38 Tax Provision is €-0.00 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €8.71. The stock has 4 warning signs investors should review.

VivoSim Labs's tax provision for the three months ended in Dec. 2025 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.00 Mil.

VivoSim Labs Tax Provision Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Tax Provision Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 -0.00

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
FRA:4OR
38GF Score
VivoSim Labs Inc FRA:4OR
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €-0.00 Mil mean?
VivoSim Labs (FRA:4OR) has a Tax Provision of €-0.00 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Tax Provision too high?
VivoSim Labs' current Tax Provision is €-0.00 Mil. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Tax Provision compare to SLXN and CDT?
VivoSim Labs' Tax Provision of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Tax Provision is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Tax Provision of €-0.00 Mil. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current Tax Provision is €-0.00 Mil. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Tax Provision is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.

Key valuation signals for FRA:4OR:

  • Tax Provision: €-0.00 Mil
  • GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score

Get the complete analysis for FRA:4OR

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.71
GF Value